T1	Participants 56 93	postmenopausal breast cancer patients
T2	Participants 432 509	metastatic breast cancer patients with previous exposure to endocrine therapy
T3	Participants 1082 1183	patients who participated in a randomized trial of adjuvant tamoxifen (1-3 years) versus observation.
